Bio-Rad Laboratories stocks have been faced with several challenges over recent years, which has led to some significant investor sell-offs. In the past five years, investors have lost 47%. Sivik Global Healthcare LLC and Marathon Asset Management Ltd both sold a substantial amount of shares, highlighting the stocks unpopularity. The company’s quarterly earnings in Q3 2025 were below estimates although revenues surpassed, causing the stock to fall further. This decline and macroeconomic uncertainty has given investors pause, despite the companies efforts to reposition itself around automation-led blood diagnostics. However, some positive shifts have been noted, including new instruments launched which boost molecular testing reach in addition to expanded partnerships, specifically with Biodesix in cancer diagnostics. Despite challenges, analysts predict it’s now an investment bet with potentially undervalued status. Institutional investors continue to favour the stock, owning 60% and price targets have been raised by Citigroup. Despite losses and inconsistent financials, steady growth was shown in Q2 2025. The upcoming Q3 2025 results will be a critical determinant as to the company's trajectory. The death of a pioneering figure at the company, Alice Schwartz, may also influence the stock’s future.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jan 2021 08:00:00 GMT to Wed, 14 Jan 2026 02:07:30 GMT -
Rating -5
- Innovation -3
- Information 5
- Rumor -1
